If you are seeing this, please disable your adblock software to view the full version of our annual report!

Leading Consensus in CGT

2021 Annual report

The ISCT ESP Ambassadors discuss their game plan leading up to ISCT 2021 New Orleans VIRTUAL. May, 2021
“Quote here”

Bruce-Resized.jpg

Bruce Levine, PhD
ISCT President (2020 – 2022)
United States

An Inspiring and Resilient Community


In a year marked deeply by the ongoing COVID-19 pandemic, our professionals drive a concerted push that grows stronger than ever as many cell and gene therapies advance from discovery to development to commercialization.

2020 marked significant challenges, and yet, there is great opportunity ahead. We are at the cusp of a new wave in cell and gene therapies, and I know that this Society will be on the leading edge.

QueenieJang.jpg

Queenie Jang, BSc (Pharmacy), MBA,
Chief Executive Officer
Canada

Re-imagining the Community in an Unprecedented Year


2020 was an unprecedented year with unprecedented challenges for our Society. In response to the COVID-19 pandemic, ISCT rapidly repositioned to meet the changed needs of a global membership largely embedded in the fight on the frontlines. 

By taking action decisively and collaboratively, this Society proved that it has what it takes to lead the field in meeting emergent and systemic challenges. From the pivot from ISCT 2020 Paris to Paris Virtual, to the expanding scope of our collaborations across the sector, to the additions we have introduced to our committees and leadership rosters, ISCT has made extraordinary impacts in a year that was unrelenting in its challenges.

Our Board of Directors

The ISCT Board of Directors consists of:

  • President (Chair of the Board of Directors)
  • President-Elect
  • Immediate Past President (Chair of the Strategic Advisory Council)
  • Global Secretary
  • Global Treasurer
  • Regional Vice Presidents

  • Chief Scientific Officer
  • Chief Regulatory Officer
  • Chief Commercialization Officer
  • 4 Elected ISCT Members
  • Senior Editor of the Society’s Journal
  • Chief Executive Officer. 

The Board of Directors is the main administrative body which manages the governance and strategic oversight of the Society.

Our Three Pillars

Since 1992, ISCT has worked to advance cell and gene therapies through a focus on translational value,
bridging experts across scientific, regulatory, and commercial fields to drive consensus and action at a global level. 

Membership: 50% outside of the United States from 60+ countries

Re-connecting to a Virtual World

Since 1992, ISCT has connected more than 21,000 delegates through our Annual Meetings and communicated with more than 38,000 cell and gene therapy professionals at cutting-edge meetings, events, webinars and seminars to translate the advancement of research into clinical adoption and standard of care over the past 27 years.

Upholding the gold standard of its signature events, ISCT faced the renewed challenge of developing and delivering a Virtual Annual Meeting in 2021. Through the guidance and leadership of the meeting co-chairs and organizing committee, ISCT put together a leading scientific program within a streaming production for over 2000 delegates at ISCT 2021 New Orleans VIRTUAL. 

Chaired By:

Jaap J. Boelens, MD, PhD
MSKCC
New York, NY, United States

Karen M. Nichols, Esq
Vertex Pharmaceuticals
Boston, MA, United States

George Muschler, MD
Cleveland Clinic
Cleveland, OH, United States

Re-connecting to a Virtual World

Since 1992, ISCT has connected more than 21,000 delegates through our Annual Meetings and communicated with more than 38,000 cell and gene therapy professionals at cutting-edge meetings, events, webinars and seminars to translate the advancement of research into clinical adoption and standard of care over the past 27 years.

Upholding the gold standard of its signature events, ISCT faced the renewed challenge of developing and delivering a Virtual Annual Meeting in 2021. Through the guidance and leadership of the meeting co-chairs and organizing committee, ISCT put together a leading scientific program within a streaming production for over 2000 delegates at ISCT 2021 New Orleans VIRTUAL. 

Chaired By:

Jaap J. Boelens, MD, PhD
MSKCC
New York, NY, United States

Karen M. Nichols, Esq
Vertex Pharmaceuticals
Boston, MA, United States

George Muschler, MD
Cleveland Clinic
Cleveland, OH, United States

2020 ISCT Career Achievement Award Winner

Malcolm K. Brenner, MD, PhD
Past President, ISCT

Fortitude and Flexibility

“Seeing the difference that mentors made to our careers taught and inspired me throughout my own efforts to mentor newcomers to the field.”

Dominating the Medicine Maker “Top 20 for 2020” List for Advanced Medicines

Celebrating 9 ISCT Leaders moving the field forward

ISCT Awards 2020

Recognizing the Achievements and Contributions of Our Membership

The 2020 Dennis Confer Innovate Award

Honoring a Visionary in the Field

ISCT offers regulatory review and consultation from cell and gene therapy experts for regulatory authorities worldwide.

Review and recommendations are made by our global task force, as well as by regional Legal and Regulatory Affairs Committees in our North America, Europe, and Australia and New Zealand regions. Each consultation consists of significant comments, suggested revisions, and edits for regulatory documentation. Below are the major guidance reviews in 2020:

Australian Parliament
3. Comments on the TGA review of TGO88
4. Response to Parliamentary Inquiry on Approval Processes

0

Regulatory Consultations and Supports

Membership to Meet Your Needs

ISCT members are the core of our Society. With member representation at every step of the translational pathway, ISCT serves to support your unique needs as we advance the CGT field together. ISCT offers tailored membership categories for IndividualsLabs, and Industry Companies – Find the membership best suited for you.

  • Reduced rates at ISCT-sponsored events, including webinars, technical workshops, research and clinical symposia, and the ISCT meetings.
  • Access to members-only web resources, including the ISCT Member Networking Database and online discussion boards.


 

Meetings – Save The Date

“Orchestrating Global CGT Translation – Building Consensus for the Path Forward”

Prepare for a Virtual Annual Meeting building on the groundbreaking success of ISCT 2020 Paris Virtual:


 

The Newly Updated ISCT Career Center
Recruiting, or looking to be recruited?

Visit the new ISCT Career Center. As part of our 2020 vision, we have continued to ensure that our job postings engage and help laboratories worldwide to expand as they seek qualified technicians, scientists, and business professionals. If you manage or are part of a lab, please inquire about our efforts to support your growth through catered job postings and outreach.

Our Volunteer Center

The ISCT Volunteer Center is the new hub designed to facilitate members seeking to join one of our 43 standing committees, or to contribute to our bimonthly e-newsletter, Telegraft.

If you have a passion for the advancement of the field of cell and gene therapy, and you wish to contribute your voice towards shaping the field by sharing your expertise and experience, please check in regularly to the volunteer center, as opportunities are expected to expand.

 

Our Committees

ISCT has 43 stakeholder committees, working in a number of scientific, commercial and regulatory disciplines within cell and gene therapy. Joining an ISCT committee is an invaluable networking opportunity, allowing you to connect with cell and gene therapy professionals from all over the world. If you would like to bolster your career by joining an ISCT committee, visit our Committees page to see how.



Showcase Your Research:

Cytotherapy

Cytotherapy, official journal of the International Society for Cell & Gene Therapy (ISCT®), publishes novel and innovative results from high quality basic, translational and clinical studies in the fields of cell and gene therapy.

Aims and Scope:

Studies evaluating the potency of experimental cell and gene therapies in clinically relevant animal models of disease and describing important advances in cell/gene-based product manufacturing and validation are welcomed. Results of clinical studies evaluating the safety and efficacy of cell and gene therapies in early and late phase trials are also of interest. In addition to Short Reports and Full-Length Articles, the journal also accepts Editorials addressing emerging trends and potential controversies in the field, and Review articles summarizing bodies of work that have made lasting impacts in the field.


Interested in showcasing your research with Cytotherapy?
Please get in touch with Dr. Patrick Hanley, Commissioning Editor

Telegraft:

Available to ISCT members around the world, Telegraft is the Society’s leading global cell therapy newsletter which updates readers on new cell and gene therapy developments, regulatory updates, and regular columns on related meetings, organizations, and events, summaries of work being done in both academic and industry labs around the world.

If you are interested in contributing an article to Telegraft, or in helping out with our editorial process, please visit here.

Tools for Learning

ISCT has a large number of valuable and comprehensive resources for ISCT members and cell and gene therapy professionals. This toolbox of resources includes a useful glossary of cell therapy terms, the ISCT Cell Therapy Bioprocessing Tools and Reagents Database, a centralized catalogue of available products for use in cell therapy processing, manufacturing, and research, as well as valuable patient resources from the innovative ISCT Presidential Task Force (PTF) on the Use of Unproven and/or Unethical Cell and Gene Therapies website, which was launched in 2018.

Visit the Cell Therapy Community Resources page to learn more.


A Lifeline for Labs

ISCT 2020 Annual report